真实世界ESME转移性乳腺癌队列中中枢神经系统转移的治疗模式与结局
基于ESME转移性乳腺癌回顾性队列16 701例患者,中位随访42.8个月,24.6%诊断为中枢神经系统转移。诊断后最常用治疗为全脑放疗(45.2%)和全身治疗(59.3%),中位OS为7.9个月(95%CI 7.2-8.4),中位NPFS为5.5个月(95%CI 5.2-5.8)。多因素分析显示年龄>70岁、三阴性肿瘤、HER2+/HR-肿瘤、≥3个转移部位及≥3线既往治疗为NPFS不良因素。
要点
- ESME队列中24.6%的MBC患者发生中枢神经系统转移。
- CNSM诊断后中位OS 7.9个月,中位NPFS 5.5个月。
- 尽管立体定向放疗进步,多数患者仍接受全脑放疗(45.2%)。
核心结论
- 研究描述了真实世界ESME转移性乳腺癌队列中中枢神经系统转移患者的治疗模式与生存结局。
- 尽管立体定向放疗有所进步,多数中枢神经系统转移患者仍接受全脑放疗,需要更多研究识别适合个体化治疗的患者亚群。
研究设计与样本
- 回顾性研究,数据来自ESME转移性乳腺癌队列,共纳入16 701例患者,中位随访42.8个月。
- 采用Kaplan-Meier法估计神经进展无生存(NPFS)和总生存(OS),采用多因素Cox比例风险模型分析NPFS的影响因素。
主要发现
- 16 701例患者中24.6%诊断为中枢神经系统转移。
- 中枢神经系统转移诊断后最常用治疗为全脑放疗(45.2%)和全身治疗(59.3%)。
- 中位OS为7.9个月(95%CI 7.2-8.4),中位NPFS为5.5个月(95%CI 5.2-5.8)。
- 多因素分析中,年龄>70岁(vs <50岁;HR=1.40;95%CI 1.24-1.57)、三阴性肿瘤(vs HER2-/HR+;HR=1.87;95%CI 1.71-2.06)、HER2+/HR-肿瘤(vs HER2-/HR+;HR=1.14;95%CI 1.02-1.27)、≥3个转移部位(vs <3;HR=1.32;95%CI 1.21-1.43)及≥3线既往治疗(vs <3;HR=1.75;95%CI 1.56-1.96)为NPFS的不良因素。
- 从筛选到中枢神经系统转移诊断的时间间隔>18个月(vs <9个月;HR=0.88;95%CI 0.78-0.98)与更长的NPFS相关。
临床怎么用
- 真实世界数据显示中枢神经系统转移后全脑放疗仍占较高比例(45.2%),临床决策需结合患者年龄、分子分型、转移部位数量及既往治疗线数评估NPFS风险。
- 三阴性及HER2+/HR-肿瘤、≥3个转移部位、≥3线既往治疗和年龄>70岁提示NPFS较差,可考虑更密切的神经影像随访或个体化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aims of the present study were to describe treatment patterns and survival outcomes in patients with central nervous system metastases (CNSM) selected among metastatic breast cancer (MBC) patients included in a retrospective study from the Epidemiological Strategy and Medical Economics (ESME) MBC cohort. METHODS: Neurological progression-free survival (NPFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Significant contributors to NPFS were determined using a multivariate Cox proportional hazards model. RESULTS: After a median follow-up of 42.8 months, of 16 701 patients included in the ESME MBC database, CNSM were diagnosed in 24.6% of patients. The most frequent treatments after diagnosis of CNSM were whole-brain radiotherapy (WBRT) (45.2%) and systemic treatment (59.3%). Median OS and NPFS were 7.9 months (95% CI: 7.2-8.4) and 5.5 months (95% CI: 5.2-5.8), respectively. In multivariate analysis, age >70 years (vs <50 years; HR = 1.40; 95% CI: 1.24-1.57), triple-negative tumours (vs HER2-/HR+; HR = 1.87; 95% CI: 1.71-2.06), HER2+/HR-tumours (vs HER2-/HR+; HR = 1.14; 95% CI: 1.02-1.27), ≥3 metastatic sites (vs < 3; HR = 1.32; 95% CI: 1.21-1.43) and ≥3 previous treatment lines (vs < 3; HR = 1.75; 95% CI: 1.56-1.96) were detrimental for NPFS. A time interval between selection and CNSM diagnosis superior to 18 months (vs <9 months; HR = 0.88; 95% CI: 0.78-0.98) was associated with longer NPFS. CONCLUSIONS: This study describes current treatment patterns of MBC patients in a "real life" setting. Despite advances in stereotactic radiation therapy, most of the patients still received WBRT. More research is warranted to identify patient subsets for tailored treatment strategies.
引用
- Pasquier D, Darlix A, Louvel G, et al. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. Eur J Cancer. 2019. PMID: 31835235. doi:10.1016/j.ejca.2019.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。